Oprah Winfrey (2024): leaving WeightWatchers, embracing GLP-1 drugs, and resetting a four-decade brand

The 2015-2023 WeightWatchers period

In October 2015, Oprah purchased approximately 10 percent of WeightWatchers (now WW International) and joined the board. The deal made Oprah a brand-equity partner with the company and integrated her personal weight narrative with the WeightWatchers product. Her involvement was widely credited with reviving the brand's relevance, and her appearances in commercials and on the OWN network as a WeightWatchers ambassador were a defining feature of the 2015-2020 era.

Through 2020-2023 the broader weight-management category began shifting in two ways. First, GLP-1 drugs (originally for diabetes, then increasingly used off-label and on-label for obesity) emerged as medically-effective weight-loss interventions. Ozempic, Wegovy, Mounjaro, and Zepbound — semaglutide and tirzepatide preparations — produced weight-loss results that conventional diet-and-behaviour programs could not match for many patients. Second, the broader public conversation began reframing weight as a complex condition involving biology, hormones, and access to medical care rather than primarily as an individual self-control issue. WeightWatchers' conventional program faced existential pressure.

The December 2023 GLP-1 disclosure and February 2024 departure

In December 2023 Oprah confirmed in a People magazine interview that she had started using a weight-loss medication, framing the decision as recognition that weight management does not hinge solely on personal self-control. The disclosure was substantial because Oprah's public weight narrative across four decades had largely centered on individual effort, will, and self-discipline. The GLP-1 framing implicitly contradicted that earlier narrative.

In February 2024 Oprah announced her departure from the WeightWatchers board. The decision was framed in two parts: first, WeightWatchers had become “a weight-health company that also administers drug medications for weight,” which was different from the diet-and-behaviour program Oprah had originally joined; second, she wanted “to be able to talk about whatever I want to talk about” in her upcoming ABC special without WeightWatchers-board-conflict concerns. She donated her entire WeightWatchers equity stake to the National Museum of African American History and Culture. WeightWatchers stock fell sharply on the news.

The March 2024 ABC special and brand repositioning

On March 18, 2024, ABC aired “An Oprah Special: Shame, Blame and the Weight Loss Revolution.” The three-hour live special featured actresses Rebel Wilson and Amber Riley, then-WeightWatchers CEO Sima Sistani, multiple medical experts including endocrinologists and obesity-medicine physicians, and Oprah herself addressing the GLP-1 conversation directly. The special framed weight as a health condition rather than a self-control failure, addressed the science of GLP-1 medications, discussed access and cost issues, and explicitly engaged with the contradiction between Oprah's previous weight-loss messaging and her current position.

The strategic effect was a substantive reset of Oprah's public position on the topic that had been central to her brand for decades. The reset drew both significant positive coverage (for honesty about the medical context of obesity) and significant criticism (from those who viewed the shift as inconsistent with her earlier audience commitments). The broader cultural conversation around GLP-1 drugs was meaningfully advanced by the special.

How RGM thinks about celebrity-brand repositioning

When clients ask about celebrity-brand repositioning under category-level pressure, the Oprah 2024 case is a useful current example. Three structural lessons. First, the disclosure-then-departure sequencing was deliberate. Oprah confirmed the GLP-1 use first (December 2023) before announcing the board departure (February 2024) and then hosting the special (March 2024). The sequencing gave audiences time to process each step rather than presenting the whole reset as a single shock. Second, the equity donation to a museum was operationally significant — it removed financial conflict of interest concerns from the special's editorial framing while also providing positive philanthropic positioning. Third, the willingness to engage directly with the contradiction between past and current positions was structurally important. Brands that try to seamlessly transition to a new position without acknowledging the old position face credibility attacks from audiences who notice the inconsistency.

The pattern is hard to copy in less-elastic celebrity brands. Oprah's decades of brand-equity gave her room to execute a substantive reset and absorb the resulting criticism; many celebrity brands could not afford the reset cost. We tell clients considering celebrity-brand-repositioning to be honest about whether the underlying audience-relationship can absorb the contradictions inherent in a substantive reset versus whether the celebrity needs to maintain consistency on the original position.

Frequently asked questions

Related